ArticleCancer diagnosis & prognosis
The Impact of Lymphoscintigraphy Visualization on the Prognosis of Early Breast Cancer Patients Undergoing Sentinel Node Biopsy: A 20-year, Single-center Experience.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Patients with early breast cancer typically have a relatively favorable prognosis, although recurrence still occurs in some cases. We hypothesized that nonvisualized lymphoscintigraphy (nonvLSG) during sentinel lymph node biopsy (SLNB) might signal lymphatic obstruction caused by tumor burden, potentially leading to poorer overall survival (OS) and relapse-free survival (RFS). Patients and Methods: This single-center retrospective cohort study included 247 patients with early breast cancer who underwent SLNB (between 1999 and 2003). Patients were grouped into visualized lymphoscintigraphy (vLSG) and nonvLSG cohorts. Clinical characteristics, SLNB outcomes, and survival data were analyzed over a median follow-up of 12.2 years (4 months-24 years). RFS and OS were compared using Kaplan‒Meier (K-M) and Cox regression analyses. Results: Of the 247 patients, 223 (90.3%) had a vLSG, whereas 24 (9.7%) had a nonvLSG. Hormone receptor positivity was lower in the nonvLSG group (62.5% Conclusion: Lymphoscintigraphy visualization status was not significantly associated with OS and RFS in patients with early breast cancer undergoing SLNB. This suggests that nonvisualization does not indicate a greater tumor burden or poorer prognosis. Clinically, this reassures that treatment strategies do not need to be adjusted solely based on nonvisualization in lymphoscintigraphy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.